In EGFR-driven ESCC, we propose that combined EGFR and AKT/mTOR pathway inhibitors may improve drug efficacy in the clinic regardless of the diversity of upstream resistance pathways involved and, given the synergistic responses seen, should enable dose-reduction strategies to limit observed toxicity. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.